BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 15555265)

  • 1. [Karyotypic and IPSS grouping of primary myelodysplastic syndromes patients: a comparison between FAB- and WHO-classification].
    Yu MH; Liu SH; Shao YQ; Hao YS; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2004 Aug; 25(8):482-5. PubMed ID: 15555265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
    Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
    Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients.
    Navarro I; Ruiz MA; Cabello A; Collado R; Ferrer R; Hueso J; Martinez J; Miguel A; Orero MT; Pérez P; Nolasco A; Carbonell F
    Leuk Res; 2006 Aug; 30(8):971-7. PubMed ID: 16423393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical significance of WHO classification and MDS 2000 classification in myelodysplastic syndromes].
    Akiba M; Matsuda A; Misumi M; Yagasaki F; Bessho M
    Rinsho Ketsueki; 2001 Dec; 42(12):1162-9. PubMed ID: 11828718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications.
    Lorand-Metze I; Pinheiro MP; Ribeiro E; de Paula EV; Metze K
    Leuk Res; 2004 Jun; 28(6):587-94. PubMed ID: 15120935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes.
    Germing U; Strupp C; Kuendgen A; Isa S; Knipp S; Hildebrandt B; Giagounidis A; Aul C; Gattermann N; Haas R
    Haematologica; 2006 Dec; 91(12):1596-604. PubMed ID: 17145595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
    Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
    Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
    Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
    Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Re-evaluation of classification of myelodysplastic syndromes with low percentage bone marrow blasts].
    Yu MH; Xu ZF; Li L; Nie L; Liu L; Zhang Y; Qin TJ; Hao YS; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):3-7. PubMed ID: 19563026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow blasts level predicts prognosis in patients with refractory cytopenia with multilineage dysplasia.
    Wang H; Wang XQ; Xu XP; Lin GW
    Eur J Haematol; 2009 Dec; 83(6):550-8. PubMed ID: 19737310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes.
    Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Dambruoso I; Lazzarino M; Bernasconi C
    Br J Haematol; 2007 May; 137(3):193-205. PubMed ID: 17408458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation.
    Cermák J; Vítek A; Michalová K
    Leuk Res; 2004 Jun; 28(6):551-7. PubMed ID: 15120930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Scoring analysis on prognosis of 63 patients with melodysplastic syndrome].
    Wei J; Chen Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):305-11. PubMed ID: 18426654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodyplastic syndromes.
    Breccia M; Carmosino I; Biondo F; Mancini M; Russo E; Latagliata R; Alimena G
    Leuk Res; 2006 Feb; 30(2):178-82. PubMed ID: 16102825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelodysplastic syndromes according to FAB and WHO classification. Single center experience.
    Haus O; Kotlarek-Haus S; Potoczek S; Czarnecka M; Duszenko E; Makowska I; Mirowska N; Kuliczkowski K
    Neoplasma; 2006; 53(2):136-43. PubMed ID: 16575469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [An analysis of prognostic factors in 80 myelodysplastic syndrome].
    Xu XQ; Wang JM; Lu SQ; Chen L; Yang JM; Zhang WP; Song XM; Xu YQ; Gong SL; Hou J; Ni X
    Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):723-7. PubMed ID: 19176004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The International Prognostic Scoring System for primary myelodysplastic syndrome].
    Sisková M; Dohnalová A; Neuwirtová R; Pĕnicková J; Karban J; Cmunt E
    Sb Lek; 2002; 103(3):333-8. PubMed ID: 12688177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes].
    Qu SQ; Liu XP; Xu ZF; Zhang Y; Qin TJ; Zhang TJ; Cui R; Hao YS; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):819-24. PubMed ID: 22339954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [WHO classification and cytogenetic analysis of 435 cases with myelodysplastic syndrome].
    Wang XQ;
    Zhonghua Nei Ke Za Zhi; 2008 Jun; 47(6):464-7. PubMed ID: 19040061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.
    Malcovati L; Porta MG; Pascutto C; Invernizzi R; Boni M; Travaglino E; Passamonti F; Arcaini L; Maffioli M; Bernasconi P; Lazzarino M; Cazzola M
    J Clin Oncol; 2005 Oct; 23(30):7594-603. PubMed ID: 16186598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.